Royalty Pharma
Price
Price
CHART BY
Historical dividends and forecast
Royalty Pharma has so far distributed $0.84 in 2024. The next dividend will be paid on 15.03.2025
CHART BY
Frequently asked questions
What is Royalty Pharma's market capitalization?
What is Royalty Pharma's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Royalty Pharma?
What are the analyst ratings and target price for Royalty Pharma's stock?
What is Royalty Pharma's revenue over the trailing twelve months?
What is the EBITDA for Royalty Pharma?
What is the free cash flow of Royalty Pharma?
How many employees does Royalty Pharma have, and what sector and industry does it belong to?
What is the free float of Royalty Pharma's shares?
Financials
- Market Cap
- $11.07B
- EPS (TTM)
- $2.557
- Free Float
- 380.55M
- P/E ratio (TTM)
- 9.75
- Revenue (TTM)
- $2.27B
- EBITDA (TTM)
- $1.54B
- Free Cashflow (TTM)
- $2.82B
Pricing
- 1D span
- $24.12$25.00
- 52W span
- $24.05$31.65
Analyst Ratings
The price target is $41.86 and the stock is covered by 11 analysts.
Buy
10
Hold
1
Sell
0
Information
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
- Employees
- 89
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- GB00BMVP7Y09
- Primary Ticker
- RPRX